Cereno Scientific Updates on CS1 EAP

Cereno Scientific reports the completion of the active 12-month study period in the Expanded Access Program (EAP) for CS1 in pulmonary arterial hypertension (PAH). The final patient visit has been conducted. The EAP provided extended treatment observation following the Phase IIa study, offering data on long-term administration in this progressive disease.

#biotech #PAH #clinicaltrials #lifescience